BIOMAT Database Logo BIOMAT Database Logo

L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma. 2011

Shinji Tsutsumi, and Satoko Morohashi, and Yasuyuki Kudo, and Harue Akasaka, and Hiroshi Ogasawara, and Masashi Ono, and Kaori Takasugi, and Keinosuke Ishido, and Kenichi Hakamada, and Hiroshi Kijima
Department of Pathology Hirosaki University School of Medicine, Hirosaki, Aomori, Japan.

OBJECTIVE Pancreatic ductal adenocarcinoma (PDAC) is one of the most extremely aggressive cancers with a poor prognosis after curative resection. L1 cell adhesion molecule (L1CAM) is a 200-220 kDa type I transmembrane glycoprotein of the immunoglobulin superfamily, which has been shown to affect the prognosis of several cancers. No clinicopathological significance of L1CAM expression has been examined at the invasive front of PDAC. In this study, we examined the relationship between L1CAM expression and clinicopathological features in PDAC by immunohistochemistry. METHODS One hundred seven surgically resected specimens of PDAC were immunohistochemically examined using a monoclonal antibody against L1CAM. RESULTS Positive expression of L1CAM was found in 23 of 107 cases with PDAC. In most cases (21/23), L1CAM expression was localized at the invasive front of the tumor tissue. Positive expression of L1CAM was significantly correlated with the histological grade, lymph node involvement, and distant metastasis. In univariate analysis, a positive expression of L1CAM was associated with short overall survival (P = 0.0002), and this was significant in multivariate analysis (P = 0.009). CONCLUSIONS L1CAM could play an important role in the invasive process in vivo, and is thought to be a good indicator of prognosis in PDAC.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Shinji Tsutsumi, and Satoko Morohashi, and Yasuyuki Kudo, and Harue Akasaka, and Hiroshi Ogasawara, and Masashi Ono, and Kaori Takasugi, and Keinosuke Ishido, and Kenichi Hakamada, and Hiroshi Kijima
L1 cell adhesion molecule (L1CAM) in invasive tumors.
September 2009, Cancer letters,
Shinji Tsutsumi, and Satoko Morohashi, and Yasuyuki Kudo, and Harue Akasaka, and Hiroshi Ogasawara, and Masashi Ono, and Kaori Takasugi, and Keinosuke Ishido, and Kenichi Hakamada, and Hiroshi Kijima
MTA2 expression is a novel prognostic marker for pancreatic ductal adenocarcinoma.
June 2013, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Shinji Tsutsumi, and Satoko Morohashi, and Yasuyuki Kudo, and Harue Akasaka, and Hiroshi Ogasawara, and Masashi Ono, and Kaori Takasugi, and Keinosuke Ishido, and Kenichi Hakamada, and Hiroshi Kijima
Expression of l1 cell adhesion molecule and morphologic features at the invasive front of colorectal cancer.
July 2011, American journal of clinical pathology,
Shinji Tsutsumi, and Satoko Morohashi, and Yasuyuki Kudo, and Harue Akasaka, and Hiroshi Ogasawara, and Masashi Ono, and Kaori Takasugi, and Keinosuke Ishido, and Kenichi Hakamada, and Hiroshi Kijima
Mesonephric-like Adenocarcinoma of the Uterine Corpus: Clinicopathological and Prognostic Significance of L1 Cell Adhesion Molecule (L1CAM) Over-expression.
October 2023, Anticancer research,
Shinji Tsutsumi, and Satoko Morohashi, and Yasuyuki Kudo, and Harue Akasaka, and Hiroshi Ogasawara, and Masashi Ono, and Kaori Takasugi, and Keinosuke Ishido, and Kenichi Hakamada, and Hiroshi Kijima
Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
September 2016, Human pathology,
Shinji Tsutsumi, and Satoko Morohashi, and Yasuyuki Kudo, and Harue Akasaka, and Hiroshi Ogasawara, and Masashi Ono, and Kaori Takasugi, and Keinosuke Ishido, and Kenichi Hakamada, and Hiroshi Kijima
Expression of C4.4A at the invasive front is a novel prognostic marker for disease recurrence of colorectal cancer.
October 2010, Cancer science,
Shinji Tsutsumi, and Satoko Morohashi, and Yasuyuki Kudo, and Harue Akasaka, and Hiroshi Ogasawara, and Masashi Ono, and Kaori Takasugi, and Keinosuke Ishido, and Kenichi Hakamada, and Hiroshi Kijima
L1 cell adhesion molecule (L1CAM) is a strong predictor for locoregional recurrences in cervical cancer.
October 2017, Oncotarget,
Shinji Tsutsumi, and Satoko Morohashi, and Yasuyuki Kudo, and Harue Akasaka, and Hiroshi Ogasawara, and Masashi Ono, and Kaori Takasugi, and Keinosuke Ishido, and Kenichi Hakamada, and Hiroshi Kijima
Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells.
April 2007, Oncogene,
Shinji Tsutsumi, and Satoko Morohashi, and Yasuyuki Kudo, and Harue Akasaka, and Hiroshi Ogasawara, and Masashi Ono, and Kaori Takasugi, and Keinosuke Ishido, and Kenichi Hakamada, and Hiroshi Kijima
Hypoxia inducible BHLHB2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma.
October 2010, Biochemical and biophysical research communications,
Shinji Tsutsumi, and Satoko Morohashi, and Yasuyuki Kudo, and Harue Akasaka, and Hiroshi Ogasawara, and Masashi Ono, and Kaori Takasugi, and Keinosuke Ishido, and Kenichi Hakamada, and Hiroshi Kijima
The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma.
October 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,
Copied contents to your clipboard!